Limits...
The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I).

Hölzl MA, Hofer J, Kovarik JJ, Roggenbuck D, Reinhold D, Goihl A, Gärtner M, Steinberger P, Zlabinger GJ - Cell. Immunol. (2010)

Bottom Line: Inhibition of SREC-I on moDCs with anti-SREC-I antibodies does not result in a decreased GP2 binding.Interaction of GP2 with SREC-I and uptake might have profound effects in antigen clearance and mediation of the immune response.In addition to SREC-I other presently unknown receptors for GP2 on DCs might be involved in this process.

View Article: PubMed Central - PubMed

Affiliation: Institute of Immunology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, A-1090 Vienna, Austria.

Show MeSH

Related in: MedlinePlus

GP2-bio binding on moDCs cannot be inhibited by anti-SREC-I antibodies. (A) GP2-bio binding to SREC-I expressing Bw cells was inhibited by coincubating GP2-bio at a concentration of 5 μg/mL with anti-SREC-I antibody at a concentration of 20 μg/mL (grey histogram). (B) Expression of SREC-I on moDCs cells was evaluated by staining cells with biotinylated SREC-I antibody at a concentration of 20 μg/mL (bold line). (C) Inhibition of GP2-bio binding to moDCs by SREC-I antibodies was investigated by coincubating moDCs with anti-SREC-I antibodies at a concentration of 20 μg/mL and GP2-bio at a concentration of 5 μg/mL (grey histogram). One representative result of three independently performed experiments is shown. MFI = Mean fluorescence intensity.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040788&req=5

f0020: GP2-bio binding on moDCs cannot be inhibited by anti-SREC-I antibodies. (A) GP2-bio binding to SREC-I expressing Bw cells was inhibited by coincubating GP2-bio at a concentration of 5 μg/mL with anti-SREC-I antibody at a concentration of 20 μg/mL (grey histogram). (B) Expression of SREC-I on moDCs cells was evaluated by staining cells with biotinylated SREC-I antibody at a concentration of 20 μg/mL (bold line). (C) Inhibition of GP2-bio binding to moDCs by SREC-I antibodies was investigated by coincubating moDCs with anti-SREC-I antibodies at a concentration of 20 μg/mL and GP2-bio at a concentration of 5 μg/mL (grey histogram). One representative result of three independently performed experiments is shown. MFI = Mean fluorescence intensity.

Mentions: In order to evaluate moDCs for the presence of additional GP2 binding receptors, we investigated the contribution of SREC-I on the total GP2 binding. Therefore, we used anti-SREC-I antibodies to block the interaction of moDCs with GP2-bio. Ligation of SREC-I on SREC-I expressing Bw cells by specific antibodies resulted in a strong decrease of the MFI, indicating that the antibodies are suitable competitors of GP2 binding (Fig. 4A). In Fig. 4B expression of SREC-I on the surface of moDCs is demonstrated. By performing the inhibition experiments as shown in Fig. 4A for SREC-I expressing Bw cells, however, no decrease in GP2-bio binding to moDCs could be observed (Fig. 4C). This indicates the presence of additional GP2 binding structures on these cells.


The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I).

Hölzl MA, Hofer J, Kovarik JJ, Roggenbuck D, Reinhold D, Goihl A, Gärtner M, Steinberger P, Zlabinger GJ - Cell. Immunol. (2010)

GP2-bio binding on moDCs cannot be inhibited by anti-SREC-I antibodies. (A) GP2-bio binding to SREC-I expressing Bw cells was inhibited by coincubating GP2-bio at a concentration of 5 μg/mL with anti-SREC-I antibody at a concentration of 20 μg/mL (grey histogram). (B) Expression of SREC-I on moDCs cells was evaluated by staining cells with biotinylated SREC-I antibody at a concentration of 20 μg/mL (bold line). (C) Inhibition of GP2-bio binding to moDCs by SREC-I antibodies was investigated by coincubating moDCs with anti-SREC-I antibodies at a concentration of 20 μg/mL and GP2-bio at a concentration of 5 μg/mL (grey histogram). One representative result of three independently performed experiments is shown. MFI = Mean fluorescence intensity.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040788&req=5

f0020: GP2-bio binding on moDCs cannot be inhibited by anti-SREC-I antibodies. (A) GP2-bio binding to SREC-I expressing Bw cells was inhibited by coincubating GP2-bio at a concentration of 5 μg/mL with anti-SREC-I antibody at a concentration of 20 μg/mL (grey histogram). (B) Expression of SREC-I on moDCs cells was evaluated by staining cells with biotinylated SREC-I antibody at a concentration of 20 μg/mL (bold line). (C) Inhibition of GP2-bio binding to moDCs by SREC-I antibodies was investigated by coincubating moDCs with anti-SREC-I antibodies at a concentration of 20 μg/mL and GP2-bio at a concentration of 5 μg/mL (grey histogram). One representative result of three independently performed experiments is shown. MFI = Mean fluorescence intensity.
Mentions: In order to evaluate moDCs for the presence of additional GP2 binding receptors, we investigated the contribution of SREC-I on the total GP2 binding. Therefore, we used anti-SREC-I antibodies to block the interaction of moDCs with GP2-bio. Ligation of SREC-I on SREC-I expressing Bw cells by specific antibodies resulted in a strong decrease of the MFI, indicating that the antibodies are suitable competitors of GP2 binding (Fig. 4A). In Fig. 4B expression of SREC-I on the surface of moDCs is demonstrated. By performing the inhibition experiments as shown in Fig. 4A for SREC-I expressing Bw cells, however, no decrease in GP2-bio binding to moDCs could be observed (Fig. 4C). This indicates the presence of additional GP2 binding structures on these cells.

Bottom Line: Inhibition of SREC-I on moDCs with anti-SREC-I antibodies does not result in a decreased GP2 binding.Interaction of GP2 with SREC-I and uptake might have profound effects in antigen clearance and mediation of the immune response.In addition to SREC-I other presently unknown receptors for GP2 on DCs might be involved in this process.

View Article: PubMed Central - PubMed

Affiliation: Institute of Immunology, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, A-1090 Vienna, Austria.

Show MeSH
Related in: MedlinePlus